You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neoadjuvant immunotherapy

Showing 1 - 25 of 6,156
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colon Cancer, Immunotherapy Trial in Chongqing (Terelizumab, CapeOx)

Not yet recruiting
  • Colon Cancer
  • Immunotherapy
  • Chongqing, China
    Daping hospital
Apr 16, 2023

Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Recruiting
  • Lung Cancer
    • Shanghai, China
      Shanghai Chest Hospital
    Jul 20, 2023

    Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced

    Recruiting
    • Gastric Cancer
    • Gastric Adenocarcinoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 4, 2023

    Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)

    Not yet recruiting
    • Colon Neoplasm
    • Hangzhou, Zhejiang, China
      Second Affiliated Hospital of Zhejiang University School of Medi
    Jun 25, 2023

    Esophagus Cancer Trial in Xiamen (Tislelizumab, Paclitaxel-albumin, Carboplatin)

    Recruiting
    • Esophagus Cancer
    • Xiamen, Fujian, China
      ShanghaiZhongshan
    Apr 8, 2023

    Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)

    Not yet recruiting
    • Carcinoma, Hepatocellular
    • (no location specified)
    Jun 15, 2023

    Esophageal Squamous Cell Carcinoma Trial in Chongqing (Tislelizumab)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chongqing, Chongqing, China
      Army Medical Center of the People's Liberation Army
    May 26, 2023

    Immunotherapy, Gastric Cancer, Rectal Cancer Trial (Terelizumab, CapeOx, Trastuzumab)

    Not yet recruiting
    • Immunotherapy
    • +4 more
    • (no location specified)
    Aug 24, 2022

    Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

    Recruiting
    • Esophageal Carcinoma
    • Neoadjuvant Immunotherapy
    • PD-1 blockade
    • +2 more
    • Beijing, Beijing, China
      Qin li
    Mar 8, 2023

    Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy Trial (radical surgery after

    Not yet recruiting
    • Advanced Gastric Carcinoma
    • +2 more
    • radical surgery after neoadjuvant immunotherapy
    • radical surgery after neoadjuvant chemotherapy
    • (no location specified)
    Feb 26, 2022

    Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

    Recruiting
    • Non-Small Cell Lung Cancer
    • Neoadjuvant immunochemotherapy
    • Neoadjuvant chemotherapy
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital,Chinese Academy of Medica
    Aug 1, 2023

    Bladder Cancer, Adult Solid Tumor Trial in Milano, Roma, Torino (Nivolumab, Visugromab (CTL-002), Placebo)

    Recruiting
    • Bladder Cancer
    • Adult Solid Tumor
    • Milano, Italy
    • +3 more
    Sep 21, 2023

    Esophagus SCC Trial in Jinan (Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin)

    Withdrawn
    • Esophagus SCC
    • Sintilimab Injection plus Paclitaxel and Cisplatin
    • Paclitaxel and Cisplatin
    • Jinan, Shandong, China
      Qilu Hospital of Shandong University
    Apr 19, 2022

    Neoadjuvant Immunotherapy Trial in Tianjin (tislelizumab+disitamab-vedotin)

    Recruiting
    • Neoadjuvant Immunotherapy
    • Tianjin, China
      The Second Hospital of Tianjin Medical University
    Apr 20, 2023

    Neoadjuvant Immunotherapy in Advanced NSCLC

    Not yet recruiting
    • Lung Cancer, Non-small Cell
    • Immunotherapy
    • San Francisco, California
      Power Life Sciences
    Jan 21, 2022

    Adenocarcinoma of Esophagogastric Junction Trial in Beijing (neoadjuvant Radiation plus SOX and PD-1 antibody)

    Not yet recruiting
    • Adenocarcinoma of Esophagogastric Junction
    • neoadjuvant Radiation plus SOX and PD-1 antibody
    • Beijing, Beijing, China
      Peking University People's Hospital
    Aug 15, 2022

    Immunotherapy, Analgesia, NSCLC Trial in Tianjin (neoadjuvant immunotherapy, Neoadjuvant chemo)

    Recruiting
    • Immunotherapy
    • +3 more
    • neoadjuvant immunotherapy
    • Neoadjuvant chemotherapy
    • Tianjin, Tianjin, China
    • +2 more
    Aug 23, 2022

    Melanoma Trial in Tampa (Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System)

    Recruiting
    • Melanoma
    • Tampa, Florida
      Moffitt Cancer Center
    May 31, 2022

    Breast Cancer Trial in Villejuif (Atezolizumab Injection, Ipatasertib, Bevacizumab)

    Recruiting
    • Breast Cancer
    • Atezolizumab Injection
    • +4 more
    • Villejuif, France
      Gustave Roussy
    Mar 9, 2022

    Locally Advanced Rectal Cancer Trial (PD-1 inhibitor, Capecitabine, Long-course radiation therapy)

    Not yet recruiting
    • Locally Advanced Rectal Cancer
    • PD-1 inhibitor
    • +2 more
    • (no location specified)
    Aug 16, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Larynx Cancer, Hypopharyngeal Cancer Trial in Shanghai (procedure, radiation, drug)

    Recruiting
    • Larynx Cancer
    • Hypopharyngeal Cancer
    • Surgery
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 9, 2023

    Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

    Recruiting
    • Non Small Cell Lung Cancer
    • anti-PD-1 or anti-PD-L1
    • +2 more
    • Shanghai, China
      Oncology Department, Shanghai Chest Hospital
    Jul 26, 2022

    Hepatocellular Carcinoma, HCC, Liver Cancer Trial in Hong Kong (Nivolumab, Hepatectomy)

    Completed
    • Hepatocellular Carcinoma
    • +2 more
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Jul 20, 2022

    Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III Trial in Shanghai (Neoadjuvant

    Recruiting
    • Esophageal Squamous Cell Carcinoma Stage II
    • Esophageal Squamous Cell Carcinoma Stage III
    • Neoadjuvant Chemoradiotherapy
    • +2 more
    • Shanghai, China
      Shanghai Zhongshan Hospital
    Jun 26, 2022